JP5138341B2 - Antiallergic agent - Google Patents

Description

  The present invention relates to an antiallergic agent characterized by containing elenolic acid or a salt thereof. Furthermore, it is related with the foodstuffs, cosmetics, or pharmaceutical containing elenolic acid or its salt.

  In recent years, inflammatory diseases including allergic diseases such as hay fever, atopic dermatitis and bronchial asthma have been rapidly increasing, and the morbidity has exceeded 20%. It has become. Allergies are classified into type I (immediate type) to type IV (delayed type), and hay fever and atopic dermatitis, which are type I allergies involving immunoglobulin E (IgE) antibodies, are very frequent. Allergic.

  When the onset process of type I allergy is divided into three stages, in the first stage, foreign antigens such as pollen, mites, and house dust enter the body, and IgE antibodies are produced by the immunocompetent cell line. IgE antibody adheres to mast cells and the like distributed at sites where allergic reactions are common, such as the respiratory tract, skin and digestive organs, and sensitization is established.

  In the second stage, when the sensitized mast cell is contacted with the antigen again, the mast cell causes a morphological change and releases chemical mediators such as histamine, serotonin and leukotriene.

  In the third stage, the released chemical mediator causes contraction of smooth muscles such as bronchial muscles and digestive organs, increased capillary permeability, neutrophil migration, platelet aggregation, etc., resulting in asthma and diarrhea Allergic symptoms such as gastrointestinal allergies, nasal allergies and urticaria appear.

  In order to prevent or treat such diseases caused by type I allergies, recent studies have shown that the above-mentioned action of inhibiting the release of chemical mediators by the second stage and the allergy caused by the third stage of released chemical mediators such as histamine The search for functional substances with higher safety has been conducted, focusing on the action of suppressing various symptoms. At the same time, those that can be used with peace of mind in a wide range of fields such as food, cosmetics, and pharmaceuticals are preferred.

As conventional techniques, an antiallergic composition derived from perilla and egoma (Patent Document 1), an antiallergic agent derived from olive leaves (Patent Document 2) and the like are disclosed.
JP 2000-86510 A JP 2007-182403 A

Moreover, an angiogenesis inhibitory effect (patent document 3) etc. are disclosed regarding elenolic acid or its salt. However, the antiallergic effect of elenolic acid or its salt is not known.
JP 2005-508856 A

  The object of the present invention is to find and provide a substance that can be easily blended into foods, cosmetics, pharmaceuticals, etc. and has excellent anti-inflammatory and anti-allergic effects from among highly safe substances derived from natural products. It is aimed.

  As a result of intensive studies on the above problems, the present inventors have found a strong histamine release inhibitory action against elenolic acid or a salt thereof, and have completed the present invention.

  That is, the present invention provides an antiallergic agent containing elenolic acid (1) or a salt thereof.

In addition to the structure of (1), the elenolic acid of the present invention may take aldehyde type (2).

  The enolic acid salt of the present invention can be used in the form of a pharmacologically acceptable salt. Examples thereof include monovalent or divalent or higher inorganic salts such as sodium, potassium, calcium, magnesium and zinc, organic salts such as organic amines and basic amino acids, or salts formed by combinations thereof.

  The present invention provides foods, cosmetics or pharmaceuticals used for the prevention or treatment of allergic diseases including the above-mentioned antiallergic agents. In addition, quasi drugs are also included in these.

Elenolic acid used in the present invention can be obtained by hydrolyzing or chemically synthesizing oleuropein using an acid or an enzyme (Non-patent Document 1).
Tetrahedron Lett, 26 (7), 865-868, 1985

  The form of the antiallergic agent according to the present invention is not particularly limited. In the case of food and medicine, for example, beverage, gum, chocolate, candy, noodles, bread, cake, biscuits, canned, retort food, livestock meat products, marine products, margarine, butter, mayonnaise, capsules, tablets, granules, Conventional food and pharmaceutical forms such as powders and lozenges can be employed. The daily dose can be 0.01 mg to 10 mg, preferably 0.1 mg to 5 mg, as elenolic acid per kg body weight, and it is desirable to administer it in two or three divided doses. If it is less than 0.01 mg / kg body weight, a sufficient effect is hardly expected. When compounding exceeds 10 mg, the enhancement of the effect is hardly recognized and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.

  In the case of cosmetics, for example, skin such as lotion, cream, emulsion, gel, aerosol, ointment, poultice, essence, pack, cleaning agent, hair tonic, bath preparation, foundation, powder, lipstick, etc. Are applicable. The blending amount is 0.001 to 20% by weight, preferably 0.01 to 10% by weight, based on the total amount. If it is less than 0.001% by weight, a sufficient effect is hardly expected. When the blending amount exceeds 20% by weight, the enhancement of the effect is hardly recognized and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.

  In addition to herbal medicines, vitamins, minerals, amino acids, etc., in addition to herbal medicines, vitamins, minerals, amino acids, etc., foods, cosmetics, pharmaceuticals containing the antiallergic agent according to the present invention, lactose, starch, cellulose, maltitol, dextrin, etc. Excipients, glycerin fatty acid esters, sucrose fatty acid esters, surfactants such as polyoxyethylene hydrogenated castor oil, coating agents such as gelatin, pullulan, shellac, zein, wheat germ oil, rice germ oil, silicone oil, etc. Fats and oils, beeswax, rice bran wax, carnauba wax and other waxes, sucrose, glucose, fructose, stevia, saccharin, sucralose and other sweeteners, and citric acid, malic acid, gluconic acid and other acidulants, glycerin, polyethylene glycol, Moisturizer such as 1,3-butylene glycol, carboxyvinyl polymer Methylcellulose, thickeners such as bentonite, may be formulated as liquid paraffin, vaseline, squalane, etc. as appropriate. Examples of herbal medicines include ginseng, American ginseng, ginseng, ganoderma, propolis, agaricus, blueberries, ginkgo leaves and extracts thereof. Examples of vitamins include oil-soluble vitamins such as vitamins D and K, and water-soluble vitamins such as vitamins B1, B2, B6, B12, C, niacin, pantothenic acid, folic acid, and biotin.

  Elenolic acid has a strong inhibitory effect on histamine release and can be used for the treatment and prevention of allergies.

  Next, examples are given as the best mode for carrying out the present invention, but the present invention is not limited to these. In the examples, (%) indicates weight (%).

Production Example 1 Preparation of Elenolic Acid Elenolic acid was prepared by acid hydrolysis of oleuropein. That is, 1000 mL of 1N sulfuric acid was added to 2 g of oleuropein (Funakoshi), treated at 100 ° C. for 1 hour, cooled, and adjusted to pH 2.0 with 6N sodium hydroxide to obtain a hydrolyzed solution. The hydrolyzed solution was separated with ethyl acetate, and the ethyl acetate layer was collected, concentrated to dryness, and then freeze-dried to obtain 680 mg of a freeze-dried product. The freeze-dried product was purified by octadecylated silica gel, concentrated to dryness, and then freeze-dried to obtain 140 mg of enolic acid.

¹ H-NMR (300 MHz, CDCl ₃ ): δ 9.91 (1H, brs), 9.68 (1H, d, J = 2 Hz), 7.65 (1H, s), 4.26 (1H, dq) , J = 2.5, 6.5 Hz), 3.73 (3H, s), 3.39 (1H, brd), 2.96 (1H, dd, J = 16, 3 Hz), 2.70 (1H) M), 2.35 (1H, dd, J = 16, 11 Hz), 1.57 (3H, d, J = 6.5 Hz)

Production Example 2 Preparation of Sodium Elenolate 100 mg of elenolic acid was dissolved in 100 mL of water, 5 mL of 0.1N sodium hydroxide was added, and freeze-dried to obtain 87 mg of sodium elenoate.

Formulation Example 1 Tablet Confectionery Formulation Amount (%)
1. Elenolic acid (Production Example 1) 2.0
2. Sugar 78.8
3. Glucose 19.0
4). Sucrose fatty acid ester 0.2
<Production method>
An appropriate amount of 70% ethanol is added to components 1 to 3, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 4 is added and tableting is performed to obtain 1 g of tablet confectionery. By taking 4 tablets of the tablet confection per day, it is possible to take 80 mg / day of enolic acid.

Formulation Example 2 Candy Formulation Amount (%)
1. Elenolic acid (Production Example 1) 1.0
2. Maltitol 70.0
3. Saccharified starch 29.0
<Production method>
Ingredients 1 to 3 are heated and melted at 120 to 170 ° C. and solidified in a mold to obtain 3 g of soot. By ingesting 3 of the persimmons per day, it is possible to ingest 90 mg / day of elenolic acid.

Comparative Formulation Example 1 Conventional Candy A conventional candy was prepared by replacing Elenolic acid (Production Example 1) with a starch saccharified product in Formulation Example 2.

Formulation Example 3 Granule formulation Formulation amount (%)
1. Sodium elenoate (Production Example 2) 4.0
2. Lactose 81.0
3. Cellulose 15.0
<Production method>
An appropriate amount of 70% ethanol is added to components 1 to 3, kneaded, extruded and granulated, and dried to obtain granules. The granule can be ingested 120 mg / day of sodium elenoate by ingesting 1 g at a time 3 times a day.

Formulation Example 4 Beverage Formulation Amount (%)
1. Elenolic acid (Production Example 1) 0.2
2. Sucrose 6.0
3. Citric acid 0.75
4). Perfume appropriate amount 5. Bring the total amount to 100 with purified water.
<Production method>
Add ingredients 1-4 to ingredient 5, stir and dissolve, filter, heat sterilize to 100 g, and fill this into a 50 g glass bottle. The beverage can ingest 100 mg / day of elenolic acid by ingesting one bottle a day.

Formulation Example 5 Lotion Formulation Amount (%)
1. Elenolic acid (Production Example 1) 0.1
2. 1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Perfume proper amount11. Make the total amount 100 with purified water <Production method>
Ingredients 1-6 and 11 and ingredients 7-10 are uniformly dissolved, mixed together, and filtered to obtain a product.

Comparative Formulation Example 2 Conventional lotion A formula obtained by replacing elenolic acid (Production Example 1) with purified water in Formulation Example 5 was used as a conventional lotion.

Formulation Example 6 Cream Formulation Amount (%)
1. Sodium elenoate (Production Example 2) 0.05
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Perfume proper amount11. Methyl paraoxybenzoate 0.2
12 Ethyl paraoxybenzoate 0.05
13.1,3-Butylene glycol 8.5
14 Make the total amount 100 with purified water <Production method>
Ingredients 2-9 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 11 to 14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.

Formulation Example 7 Emulsion
Formulation Amount (%)
1. Sodium elenoate (Production Example 2) 0.5
2. Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5. Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate
(20 EO) 2.0
9. Perfume appropriate amount10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Make the total amount 100 with purified water <Production method>
Ingredients 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.

Formulation Example 8 Gel formulation Formulation amount (%)
1. Sodium elenoate (Production Example 2) 1.0
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
5. Perfume appropriate amount 6. 1,3-butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Make the total amount 100 with purified water <Production method>
Ingredients 2 to 5 and ingredients 1 and 6 to 11 are uniformly dissolved, and both are mixed to obtain a product.

Formulation Example 9 Foundation Formulation Amount (%)
1. Elenolic acid (Production Example 1) 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20EO) 1.0
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Sodium carboxymethylcellulose 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12 Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14 Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Perfume proper amount19. Make the total amount 100 with purified water <Production method>
Ingredients 2 to 8 are dissolved by heating and kept at 80 ° C. to form an oil phase. Swell component 9 well in component 19, then add components 1 and 10-13 and mix uniformly. To this, components 14 to 17 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oil phase is added to this aqueous phase with stirring, cooled, component 18 is added at 45 ° C., and cooled to 30 ° C. with stirring to give a product.

Formulation Example 10 Hair Tonic Formulation Amount (%)
1. Elenolic acid (Production Example 1) 1.0
2. Ethanol 63.0
3. Glycerin 2.0
4). Make the total amount 100 with purified water <Production method>
Components 1 to 3 are dissolved in Component 4 to obtain a product.

Formulation Example 11 Bath formulation Formulation amount (%)
1. Elenolic acid (Production Example 1) 1.0
2. Sodium bicarbonate 50.0
3. Yellow No. 202 (1) Appropriate amount 4. Perfume appropriate amount 5. Make the total amount 100 with sodium sulfate <Production method>
Ingredients 1 to 5 are uniformly mixed to obtain a product.

Test Example 1 Histamine Release Inhibition Test of Elenolic Acid Wistar male rat (8 weeks old) Mast cell suspension collected from the abdominal cavity was adjusted to 2 × 10 ⁵ cells / mL, and 650 μL of the rat containing IgE antibody 320 μL of an 8-fold dilution of serum was added and incubated at 37 ° C. for 30 minutes. Next, elenolic acid (Production Example 1) or sodium elenoate (Production Example 2) was added to 0.1 or 0.3 mg / mL and incubated at 37 ° C. for 10 minutes. Furthermore, after adding 20 μg of ovalbumin and 30 μg of phosphatidylserine and incubating at 37 ° C. for 20 minutes for antigen stimulation, the mast cell suspension was cooled to 4 ° C. to stop the reaction. After cooling sufficiently, the mixture was centrifuged at 3,000 rpm for 5 minutes, and the supernatant containing the released histamine was collected.
The supernatant histamine was quantified by adding hydrochloric acid in n-heptane to form histamine hydrochloride, and then measuring the fluorescence intensity by the o-phthalaldehyde method.

  As shown in Table 1, elenolic acid or sodium elenoate showed a histamine release inhibitory effect in a concentration-dependent manner.

Test Example 2 Pollen allergy improvement effect of elenolic acid 30 subjects with subjective symptoms of hay fever were ingested 3 candy per prescription example 2 per day for 1 month, questionnaire about hay fever symptoms before and after ingestion And examined the improvement effect. In addition, about the conventional candy of the comparative prescription example 1, the test was implemented to 15 persons among said 30 test subjects as a placebo group.

  As shown in Table 2, when candy containing elenolic acid was ingested for one month, the symptoms of hay fever, “throat discomfort”, “nasal discomfort”, and “number of sneezing” were improved. On the other hand, as shown in Table 3, the placebo group that ingested candy that does not contain elenolic acid for 1 month showed no hay fever improvement effect.

Test Example 3 Effect of Elenolic Acid on Improvement of Atopic Dermatitis To 20 subjects with subjective symptoms of atopic dermatitis, lotion described in Formulation Example 5 was applied 3 times a day for 1 month, and atopic properties before and after application A questionnaire was conducted on the symptoms of dermatitis, and the improvement effect was examined. For the conventional lotion described in Comparative Prescription Example 2, the test was conducted on 10 of the 20 subjects as a placebo group.

  As shown in Table 4, when a skin lotion containing elenolic acid was applied for 1 month, the symptoms of atopic dermatitis, “eczema”, “skin itching” and “rough skin” were improved. On the other hand, as shown in Table 5, the placebo group that ingested the skin lotion not containing elenolic acid for 1 month did not show the atopic dermatitis improving effect.

  The antiallergic agent of the present invention can be applied to alleviate or improve allergic symptoms caused by pollen, house dust and the like.

Claims (5)

An antiallergic agent comprising elenolic acid (1) or a salt thereof.

The antiallergic agent according to claim 1, wherein the antiallergic effect is a histamine release inhibitory effect. A hay fever ameliorating agent comprising 0.01 to 10% by weight of the antiallergic agent according to claim 1 or 2. An atopic dermatitis ameliorating agent comprising 0.01 to 10% by weight of the antiallergic agent according to claim 1 or 2. A cosmetic comprising 0.01 to 10% by weight of the antiallergic agent according to claim 1 or 2.